Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a ...

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.

PDS Biotechnology (PDSB) reaffirmed the Company’s guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune HPV plus ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...

Medical announced an approval from the U.S. Food and Drug Administration, FDA, of an Investigational Device Exemption IDE, ...